At the time of my last article in April, VKTX reported data from a study of four weeks treatment with oral VK2735 in obese subjects, but only up to 40 mg (3.7% placebo-adjusted weight loss).

In the MAD trial, oral VK2735 also demonstrated encouraging safety and tolerability through 28 days of once-daily dosing at doses up to and including 100 mg. The majority (99%) of observed ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm.

The oral formulation of VK2735 is currently in a 13-week ... At the time, the company reported that the highest, 15-mg dose of the injectable was linked to mean weight loss of 14.7% after 13 ...

Eli Lilly & Co. (NYSE: LLY) launched its own GLP-1/GIP dual agonist treatment for obesity, Zepbound, in December 2023.

VK2735 is being developed as both an injectable and an oral treatment ... had a 14.9% mean weight loss on the 2.4 mg weekly injection after 68 weeks during its Phase 3 STEP 1 study.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...